1.In lung cancer, Pembrolizumab, the PD-1 humanized antibody made the Breakthrough cut but keeping activity in first line as well advanced Non small cell lung cancer. Given at 10mg/kg every 3 to 3 weeks,
at least half of the patient will respond whae they have the PDL-1 receptor!
No patient today should die of this disease if they have the receptor, without seeing PEMBRO!
2.In ALL, CD19 targeted chimeric Antigen Receptor (CAR received Breakthrough designation and Blinatomomab....These are huge discoveries to say the least and in deisease notoriously mortal! With unprecedented response rates 80 to 100 % according to study populations !And manageable side effects!
3.The excellent Ibrutinib is "tripling" disease free survival and doubling survival in certain CLL....these are again unprecedented results of new target therapy
the standard chemotherapy is soon becoming remotely cited in current Oncology journal
and there is more to come....
Lenvatinib----Thyroid cancer
Bladder cancers----MPDL328A
Now Jakafi -Xelaoda in pancreatic cancer!!!
behind PEMBRO, NECITUMUMAB sneaking in NSCL cancers!
Belinostat for Peripheral T-cell lymphoma
Finally we see the Anti-BCL2 working in CLL--ABT-199, here we are acing the mechanism of non dying cells!
And embracing the 2nd generation anti -EGFR!!!! science is on the Go....enemies working their best to politicize science...CRBCM working hard despite ....
No comments:
Post a Comment